Wissenschaftliche Publikationen

Melchart D, Löw P, Wühr E, Kehl V, Weidenhammer W:

Effects of a tailored lifestyle self-management intervention (TALENT) study on weight reduction: a randomized controlled trial

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2017:10 235–245

Löw P, Weber C, Harrer E, Rohwer P, Kalden JR, Harrer T:
CD80 expression on monocytes in HIV-infected patients.
J Acquir Immune Defic Syndr Hum Retrovirol 15(4): 264-8, 1997.

Löw P, Neipel F, Rascu A, Steininger H, Manger B, Fleckenstein B, Kalden JR, Harrer T:
Supression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi´s sarcoma and HHV-8 associated hemophagocytic syncrome.
Eur J Med Res, 3(10): 461-464, 1998.

Grunke M, Dechant C, Löw P, Kalden JR and Harrer T:
Hydroxyurea as Part of an Salvage Regimen for Heavily Pretreated Patients with Advanced HIV Infection.
J Acquir Immune Defic Syndr Hum Retrovirol 21:424-426. 1999

Kolowos W, Schmitt M, Herrmann M, Harrer E, Löw P, Kalden JR, Harrer T:
Biased T-cell receptor repertoire in HIV-infected patients due to clonal expansion of HIV-1-RT-specific CTL clones. Journal of Immunology 162:7525-7533, 1999

Hauber I, Harrer T, Löw P, Schmitt M and Hauber J:
Determination of HIV-1 circular DNA as a surrogate marker for residual virus replication in patients with undetectable virus loads. AIDS 14:2619-2621.

Van Vaerenbergh K, Harrer T, Schmit JC, Schmidt B, Walter H, Fontaine E, Schmitt M, Van Laethem K, Rascu A, De Vroey V, Grünke M, Löw P, Van Ranst M, De Clercq E, Desmyter J, Vandamme AM:
Initiation of HAART in drug-naive HIV-1 patients prevents viral breakthrough for up to 43 months in 60% of the patients.
AIDS Research and Human Retroviruses 18 (6): 419-426, 2002.

Walter H, Löw P, Harrer T, Schmitt M, Schwingel E, Tschochner M, Helm M, Korn K, Uberla K, Schmidt B:
No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual.
J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):137-46.

Lancet. 1997 May 17;349(9063):1413-21.
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
(P. Löw listed as participant for the University Hospital Erlangen in the addendum of the CAESAR Study Group)

Sprechzeiten

nach Vereinbarung

Mo – Fr:   8.00 – 12.00 Uhr
Mo: 15.00 – 18.00 Uhr
Di: 15.00 – 17.00 Uhr
Do: 15.00 – 19.00 Uhr

Anschrift

Praxis Doktores Löw

im BRK-Seniorenzentrum
an der Altmühltherme
Weißenburger Straße 7c
91757 Treuchtlingen

T 09142-8624
F 09142-9739796

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z